|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 11663 |
FusionGeneSummary for ENTPD5_OLFM2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ENTPD5_OLFM2 | Fusion gene ID: 11663 | Hgene | Tgene | Gene symbol | ENTPD5 | OLFM2 | Gene ID | 957 | 93145 |
| Gene name | ectonucleoside triphosphate diphosphohydrolase 5 | olfactomedin 2 | |
| Synonyms | CD39L4|NTPDase-5|PCPH | NOE2|NOELIN2|NOELIN2_V1|OlfC | |
| Cytomap | 14q24.3 | 19p13.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | ectonucleoside triphosphate diphosphohydrolase 5CD39 antigen-like 4CD39-like 4ER-UDPaseGDPase ENTPD5NTPDase 5Pcph proto-oncogene proteinUDPase ENTPD5guanosine-diphosphatase ENTPD5nucleoside diphosphataseproto-oncogene CPHuridine-diphosphatase E | noelin-2neuronal olfactomedin related ER localized protein 2 | |
| Modification date | 20180519 | 20180519 | |
| UniProtAcc | O75356 | O95897 | |
| Ensembl transtripts involved in fusion gene | ENST00000557325, ENST00000334696, ENST00000556242, ENST00000554664, | ENST00000264833, ENST00000590841, | |
| Fusion gene scores | * DoF score | 7 X 4 X 6=168 | 6 X 4 X 6=144 |
| # samples | 7 | 7 | |
| ** MAII score | log2(7/168*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/144*10)=-1.04064198449735 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: ENTPD5 [Title/Abstract] AND OLFM2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | Oncogene involved fusion gene, in-frame and retained their domain. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | OLFM2 | GO:0009306 | protein secretion | 21228389 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | SKCM | TCGA-FS-A1ZP-06A | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000557325 | ENST00000264833 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| 5CDS-intron | ENST00000557325 | ENST00000590841 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| Frame-shift | ENST00000334696 | ENST00000264833 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| 5CDS-intron | ENST00000334696 | ENST00000590841 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| intron-3CDS | ENST00000556242 | ENST00000264833 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| intron-intron | ENST00000556242 | ENST00000590841 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| intron-3CDS | ENST00000554664 | ENST00000264833 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
| intron-intron | ENST00000554664 | ENST00000590841 | ENTPD5 | chr14 | 74453517 | - | OLFM2 | chr19 | 9971470 | - |
Top |
FusionProtFeatures for ENTPD5_OLFM2 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ENTPD5 | OLFM2 |
| Uridine diphosphatase (UDPase) that promotes protein N-glycosylation and ATP level regulation. UDP hydrolysis promotesprotein N-glycosylation and folding in the endoplasmic reticulum,as well as elevated ATP consumption in the cytosol via an ATPhydrolysis cycle. Together with CMPK1 and AK1, constitutes an ATPhydrolysis cycle that converts ATP to AMP and results in acompensatory increase in aerobic glycolysis. The nucleotidehydrolyzing preference is GDP > IDP > UDP, but not any othernucleoside di-, mono- or triphosphates, nor thiaminepyrophosphate. Plays a key role in the AKT1-PTEN signaling pathwayby promoting glycolysis in proliferating cells in response tophosphoinositide 3-kinase (PI3K) signaling.{ECO:0000269|PubMed:10400613}. | Involved in transforming growth factor beta (TGF-beta)-induced smooth muscle differentiation. TGF-beta induces expressionand translocation of OLFM2 to the nucleus where it binds to SRF,causing its dissociation from the transcriptional repressorHEY2/HERP1 and facilitating binding of SRF to target genes(PubMed:25298399). Plays a role in AMPAR complex organization (Bysimilarity). Is a regulator of vascular smooth-muscle cell (SMC)phenotypic switching, that acts by promoting RUNX2 and inhibitingMYOCD binding to SRF. SMC phenotypic switching is the processthrough which vascular SMCs undergo transition between a quiescentcontractile phenotype and a proliferative synthetic phenotype inresponse to pathological stimuli. SMC phenotypic plasticity isessential for vascular development and remodeling (By similarity).{ECO:0000250|UniProtKB:Q568Y7, ECO:0000250|UniProtKB:Q8BM13,ECO:0000269|PubMed:25298399}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | >OLFM2 | chr14:74453517 | chr19:9971470 | ENST00000264833 | - | 0 | 6 | 136_193 | 21 | 455 | Coiled coil | Ontology_term=ECO:0000255 |
| Tgene | >OLFM2 | chr14:74453517 | chr19:9971470 | ENST00000264833 | - | 0 | 6 | 58_85 | 21 | 455 | Coiled coil | Ontology_term=ECO:0000255 |
| Tgene | >OLFM2 | chr14:74453517 | chr19:9971470 | ENST00000264833 | - | 0 | 6 | 194_446 | 21 | 455 | Domain | Olfactomedin-like |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ENTPD5_OLFM2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_ENTPD5_ENST00000557325_chr14_74453517_-_OLFM2_ENST00000264833_chr19_9971470_-_533aa MATSWGTVFFMLVVSCVCSAVSHRNQQTWFEGIFLSSMCPINVSASTLYGIMFDAGSTGTRIHVYTFVQKMPGQLPILEGEVFDSVKPGL SAFVDQPKQTLFQNPEEGWQLYTSAQAPDGKCICTAVIPAQSTCSRDGRSRELRQLMEKVQNVSQSMEVLELRTYRDLQYVRGMETLMRS LDARLRAADGSLSAKSFQELKDRMTELLPLSSVLEQYKADTRTIVRLREEVRNLSGSLAAIQEEMGAYGYEDLQQRVMALEARLHACAQK LGCGKLTGVSNPITVRAMGSRFGSWMTDTMAPSADSRVWYMDGYYKGRRVLEFRTLGDFIKGQNFIQHLLPQPWAGTGHVVYNGSLFYNK YQSNVVVKYHFRSRSVLVQRSLPGAGYNNTFPYSWGGFSDMDFMVDESGLWAVYTTNQNAGNIVVSRLDPHTLEVMRSWDTGYPKRSAGE |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_ENTPD5_ENST00000557325_chr14_74453517_-_OLFM2_ENST00000264833_chr19_9971470_-_1599nt ATGGCCACTTCTTGGGGCACAGTCTTTTTCATGCTGGTGGTATCCTGTGTTTGCAGCGCTGTCTCCCACAGGAACCAGCAGACTTGGTTT GAGGGTATCTTCCTGTCTTCCATGTGCCCCATCAATGTCAGCGCCAGCACCTTGTATGGAATTATGTTTGATGCAGGGAGCACTGGAACT CGAATTCATGTTTACACCTTTGTGCAGAAAATGCCAGGACAGCTTCCAATTCTAGAAGGGGAAGTTTTTGATTCTGTGAAGCCAGGACTT TCTGCTTTTGTAGATCAACCTAAGCAGACTCTCTTCCAGAACCCAGAAGAGGGCTGGCAGCTGTACACCTCAGCCCAGGCCCCTGACGGG AAATGCATCTGCACGGCCGTGATCCCAGCGCAGAGTACCTGCTCTCGAGATGGCAGGAGTCGGGAGCTGCGGCAACTGATGGAGAAGGTC CAGAACGTCTCCCAGTCCATGGAGGTCCTTGAGTTGCGGACGTATCGCGACCTCCAGTATGTACGCGGCATGGAGACCCTCATGCGGAGC CTGGATGCGCGGCTCCGGGCAGCTGATGGGTCCCTCTCGGCCAAGAGCTTCCAGGAGCTGAAGGACAGGATGACGGAACTGTTGCCCCTG AGCTCGGTCCTGGAGCAGTACAAGGCAGACACGCGGACCATTGTACGCTTGCGGGAGGAGGTGAGGAATCTCTCCGGCAGTCTGGCGGCC ATTCAGGAGGAGATGGGTGCCTACGGGTATGAGGACCTGCAGCAACGGGTGATGGCCCTGGAGGCCCGGCTCCACGCCTGCGCCCAGAAG CTGGGCTGTGGGAAGCTGACCGGGGTCAGTAACCCCATCACCGTTCGGGCCATGGGGTCCCGCTTCGGCTCCTGGATGACTGACACGATG GCCCCCAGTGCGGATAGCCGGGTCTGGTACATGGATGGCTATTACAAAGGCCGCCGGGTCCTGGAGTTCCGTACCCTGGGAGACTTCATC AAAGGCCAGAACTTTATCCAGCACCTGCTGCCCCAGCCGTGGGCGGGCACGGGCCACGTGGTGTACAACGGCTCCCTGTTCTATAACAAG TACCAGAGCAACGTGGTGGTCAAATACCACTTCCGCTCGCGCTCTGTGCTGGTGCAGAGGAGCCTCCCGGGCGCCGGTTACAACAACACC TTCCCCTACTCCTGGGGCGGCTTCTCCGACATGGACTTCATGGTGGACGAGAGCGGGCTCTGGGCTGTGTACACCACCAACCAGAACGCG GGCAACATCGTGGTCAGCCGGCTGGACCCGCACACCCTCGAGGTCATGCGGTCCTGGGACACCGGCTACCCCAAGCGCAGCGCTGGCGAG GCCTTCATGATCTGCGGTGTGCTCTACGTGACCAACTCCCACCTGGCTGGGGCCAAGGTCTACTTCGCCTATTTTACCAACACGTCCAGT TACGAGTACACGGACGTGCCCTTCCACAACCAGTATTCCCACATCTCGATGCTGGATTACAACCCCCGGGAGCGCGCCCTCTATACCTGG |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_ENTPD5_ENST00000557325_chr14_74453517_-_OLFM2_ENST00000264833_chr19_9971470_-_2419nt TTCCTTGTTCCTGGTCAACAAAGAAATGTGGAGTGTCTTGGCTGAATCCTCATACAGACAAGATCATTATGGTGCTGTTAGGTAGGACTT GTATCCAGATGTAAGGTTGAAAAAGTGATATAATAAAGGAACCAAGGAGAAAATTCAGAAGGAAAGAAAAAATTGGTCTCACTCTGTCAC CGAGGCTGGAGTACAGTGGTGCAATCACAGCTCACGGCAGCTTCAAACTCCTGGGCTCAAGCGATCCTCCTGCCTCACCCTCCCGAGTAG CTGAGACTACAGCCTCTGCAGGTGTGCGAGCAGGATTGCTTCTGCAACAAAAGCCTCCACCCAGCCACATCTTGGGAAAAGAATGGCCAC TTCTTGGGGCACAGTCTTTTTCATGCTGGTGGTATCCTGTGTTTGCAGCGCTGTCTCCCACAGGAACCAGCAGACTTGGTTTGAGGGTAT CTTCCTGTCTTCCATGTGCCCCATCAATGTCAGCGCCAGCACCTTGTATGGAATTATGTTTGATGCAGGGAGCACTGGAACTCGAATTCA TGTTTACACCTTTGTGCAGAAAATGCCAGGACAGCTTCCAATTCTAGAAGGGGAAGTTTTTGATTCTGTGAAGCCAGGACTTTCTGCTTT TGTAGATCAACCTAAGCAGACTCTCTTCCAGAACCCAGAAGAGGGCTGGCAGCTGTACACCTCAGCCCAGGCCCCTGACGGGAAATGCAT CTGCACGGCCGTGATCCCAGCGCAGAGTACCTGCTCTCGAGATGGCAGGAGTCGGGAGCTGCGGCAACTGATGGAGAAGGTCCAGAACGT CTCCCAGTCCATGGAGGTCCTTGAGTTGCGGACGTATCGCGACCTCCAGTATGTACGCGGCATGGAGACCCTCATGCGGAGCCTGGATGC GCGGCTCCGGGCAGCTGATGGGTCCCTCTCGGCCAAGAGCTTCCAGGAGCTGAAGGACAGGATGACGGAACTGTTGCCCCTGAGCTCGGT CCTGGAGCAGTACAAGGCAGACACGCGGACCATTGTACGCTTGCGGGAGGAGGTGAGGAATCTCTCCGGCAGTCTGGCGGCCATTCAGGA GGAGATGGGTGCCTACGGGTATGAGGACCTGCAGCAACGGGTGATGGCCCTGGAGGCCCGGCTCCACGCCTGCGCCCAGAAGCTGGGCTG TGGGAAGCTGACCGGGGTCAGTAACCCCATCACCGTTCGGGCCATGGGGTCCCGCTTCGGCTCCTGGATGACTGACACGATGGCCCCCAG TGCGGATAGCCGGGTCTGGTACATGGATGGCTATTACAAAGGCCGCCGGGTCCTGGAGTTCCGTACCCTGGGAGACTTCATCAAAGGCCA GAACTTTATCCAGCACCTGCTGCCCCAGCCGTGGGCGGGCACGGGCCACGTGGTGTACAACGGCTCCCTGTTCTATAACAAGTACCAGAG CAACGTGGTGGTCAAATACCACTTCCGCTCGCGCTCTGTGCTGGTGCAGAGGAGCCTCCCGGGCGCCGGTTACAACAACACCTTCCCCTA CTCCTGGGGCGGCTTCTCCGACATGGACTTCATGGTGGACGAGAGCGGGCTCTGGGCTGTGTACACCACCAACCAGAACGCGGGCAACAT CGTGGTCAGCCGGCTGGACCCGCACACCCTCGAGGTCATGCGGTCCTGGGACACCGGCTACCCCAAGCGCAGCGCTGGCGAGGCCTTCAT GATCTGCGGTGTGCTCTACGTGACCAACTCCCACCTGGCTGGGGCCAAGGTCTACTTCGCCTATTTTACCAACACGTCCAGTTACGAGTA CACGGACGTGCCCTTCCACAACCAGTATTCCCACATCTCGATGCTGGATTACAACCCCCGGGAGCGCGCCCTCTATACCTGGAACAACGG CCACCAGGTGCTCTACAATGTCACCCTGTTTCACGTCATCAGCACCTCTGGGGACCCCTGAGCCAATGCTGTGGCTCGGGCTGCTGCCTG GGGGGCCTCTGGGGGCTGGGGGCCCTTTTCATTCTGCCTGTGTCCCTCAAGGGTGATCTCTCTGTCTCTGTCACGCCCTTTCTCCCCGCC TTTTTGCTGGGCTTTTGTTCTCTGCCTATGTATTTCTGTCTATTTTTTCAATTTCCCCTCTTCTCCTTTATTGATCTCTGCTTTTAATAC ACCACTTCTTTCTTTCTGCCTTTTTATGGATGTCTTTTTCTTTTTATGGCTCTGGTTCTCCAGTTCTTTCCGTCTCTGCCTCTCTCTGTC TCTCTCTCTCTGTCCTTCCACCCCTCCCTCCTTGCTTCCCACCCATTCCTCATCCCTCACTCCCACCCCCACCCCCACCCCCAGGAGTTG |
Top |
FusionGenePPI for ENTPD5_OLFM2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| ENTPD5 | MXI1, IDS, FBXO6, BCHE, LYZL2 | OLFM2 | SRSF5, ST13, BLOC1S6, KRTAP10-3, OLFM1, ZFHX4, RNF40, TUBB1, DVL2, FEM1B, OLFM3, KDM5C, MSTO1, LRIF1, ZSWIM8, CBY1, EGFL7, DTNB, SDF2L1, DPYSL4, METTL3, PEX6, GALNS, BMP7, ZNF507, C15orf39, FUT11, NCOR1, CTDNEP1, BANP, VCPIP1, USP54, GPATCH8, N4BP2L2, DNAJB9, HAUS8 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ENTPD5_OLFM2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ENTPD5_OLFM2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|